BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36306447)

  • 21. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
    Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
    Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
    Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells.
    Rossi UA; Finocchiaro LME; Glikin GC
    Anticancer Agents Med Chem; 2017; 17(5):754-761. PubMed ID: 27677689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib-Encapsulated Dual Responsive Copolymeric Nanoparticles for Gallbladder Cancer Targeted Therapy.
    Chen M; Juengpanich S; Li S; Topatana W; Lu Z; Zheng Q; Cao J; Hu J; Chan E; Hou L; Chen J; Chen F; Liu Y; Jiansirisomboon S; Gu Z; Tongpeng S; Cai X
    Adv Sci (Weinh); 2022 Mar; 9(7):e2103895. PubMed ID: 35068071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.
    Tibullo D; Barbagallo I; Giallongo C; Vanella L; Conticello C; Romano A; Saccone S; Godos J; Di Raimondo F; Li Volti G
    Oncotarget; 2016 May; 7(20):28868-80. PubMed ID: 26930712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.
    Korani M; Korani S; Zendehdel E; Jaafari MR; Sathyapalan T; Sahebkar A
    Anticancer Agents Med Chem; 2020; 20(6):643-650. PubMed ID: 31985384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes.
    Stadelmann B; Aeschbacher D; Huber C; Spiliotis M; Müller J; Hemphill A
    PLoS Negl Trop Dis; 2014 Dec; 8(12):e3352. PubMed ID: 25474446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.
    Shen J; Wang R; Wang Q; Zhang M; Liu C; Tao Z; Su G
    Aging (Albany NY); 2020 Dec; 13(1):411-423. PubMed ID: 33290262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine-modified poly(ε-caprolactone) micelles for pH controlled delivery of bortezomib.
    Liu L; Wang S; Qi P; Song S; Yang Y; Shi J; Han G
    Int J Pharm; 2020 Nov; 590():119885. PubMed ID: 32949619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Curcumin-Loaded Blood-Stable Polymeric Micelles for Enhancing Therapeutic Effect on Erythroleukemia.
    Gong F; Chen D; Teng X; Ge J; Ning X; Shen YL; Li J; Wang S
    Mol Pharm; 2017 Aug; 14(8):2585-2594. PubMed ID: 28199114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biodistribution of biodegradable polymeric nano-carriers loaded with busulphan and designed for multimodal imaging.
    Asem H; Zhao Y; Ye F; Barrefelt Å; Abedi-Valugerdi M; El-Sayed R; El-Serafi I; Abu-Salah KM; Hamm J; Muhammed M; Hassan M
    J Nanobiotechnology; 2016 Dec; 14(1):82. PubMed ID: 27993139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
    Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
    Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
    Li C; Hu J; Li W; Song G; Shen J
    Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A complex micellar system co-delivering curcumin with doxorubicin against cardiotoxicity and tumor growth.
    Zhang D; Xu Q; Wang N; Yang Y; Liu J; Yu G; Yang X; Xu H; Wang H
    Int J Nanomedicine; 2018; 13():4549-4561. PubMed ID: 30127606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulforaphane delivery using mPEG-PCL co-polymer nanoparticles to breast cancer cells.
    Danafar H; Sharafi A; Kheiri Manjili H; Andalib S
    Pharm Dev Technol; 2017 Aug; 22(5):642-651. PubMed ID: 26916923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors.
    Molavi O; Ma Z; Mahmud A; Alshamsan A; Samuel J; Lai R; Kwon GS; Lavasanifar A
    Int J Pharm; 2008 Jan; 347(1-2):118-27. PubMed ID: 17681440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual-acidity-labile polysaccharide-di-drugs conjugate for targeted cancer chemotherapy.
    Li D; Su T; Ma L; Yin F; Xu W; Ding J; Li Z
    Eur J Med Chem; 2020 Aug; 199():112367. PubMed ID: 32474350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
    Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
    Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug release and kinetic models of anticancer drug (BTZ) from a pH-responsive alginate polydopamine hydrogel: Towards cancer chemotherapy.
    Rezk AI; Obiweluozor FO; Choukrani G; Park CH; Kim CS
    Int J Biol Macromol; 2019 Dec; 141():388-400. PubMed ID: 31493453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
    Dutta D; Liu J; Wen K; Kurata K; Fulciniti M; Gulla A; Hideshima T; Anderson KC
    Blood Cancer J; 2023 Dec; 13(1):184. PubMed ID: 38072962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.